BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451

 
• By Sten Stovall

BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.

Lung cancer
Bristol-Myers Squibb's Checkmate-451 Tested Opdivo and Yervoy in Small cell Lung Cancer • Source: Shutterstock

More from Clinical Trials

More from R&D